Roivant Sciences Rises on Positive Phase 2 Trial Data from Immunovant's Drug

Roivant Sciences (ROIV) saw a sharp rise in stock price after its subsidiary, Immunovant (IMVT), released initial positive results from a Phase 2 trial of IMVT-1402 for rheumatoid arthritis. The data showed promising outcomes at the Week 16 mark.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · May 20, 2026, 14:10 UTC

Roivant Sciences Rises on Positive Phase 2 Trial Data from Immunovant's Drug

Tickers: $IMVT $ROIV

Topics: biotech drug development pharma rheumatoid arthritis

Read the full article at Seeking Alpha

More World news

Nvidia CEO Jensen Huang Resigns Amid Board Investigation The Verge · November 12, 2026, 15:48 UTC
GFL Environmental Shares Decline Following Preferred Share Conversion and Block Trade Seeking Alpha · November 12, 2026, 15:48 UTC
Medical Facilities Corp. Announces CAD 0.09 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 15:45 UTC
Micron Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 15:44 UTC
Wirex Launches Navoka AI Agent with Dedicated Bank Account and Card PR Newswire · November 12, 2026, 15:44 UTC
Mobility Global Shares Rise 12% Following Q3 Earnings Beat and Improved EBITDA Outlook Seeking Alpha · November 12, 2026, 15:44 UTC
Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement Motley Fool · November 12, 2026, 15:39 UTC
National Vision Reports Q3 2026 Revenue Growth Driven by Higher Average Ticket Motley Fool · November 12, 2026, 15:40 UTC
Okeanis Eco Tankers Reports Record Q3 2026 Results Driven by High Freight Rates Motley Fool · November 12, 2026, 15:41 UTC
Nvidia Shares Plunge Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:35 UTC